These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 10866318)
1. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines. Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318 [TBL] [Abstract][Full Text] [Related]
2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
3. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400 [TBL] [Abstract][Full Text] [Related]
4. In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines, tumor eradication and protective antitumor immunity. Sun Y; Peng D; Lecanda J; Schmitz V; Barajas M; Qian C; Prieto J Gene Ther; 2000 Sep; 7(17):1467-76. PubMed ID: 11001366 [TBL] [Abstract][Full Text] [Related]
5. CD4 T cell dependent tumor immunity stimulated by dendritic cell based vaccine. Zhang S; Li W; Xia Z; Mao Y Biochem Biophys Res Commun; 2011 Sep; 413(2):294-8. PubMed ID: 21893031 [TBL] [Abstract][Full Text] [Related]
6. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127 [TBL] [Abstract][Full Text] [Related]
8. Development of cell-based tuberculosis vaccines: genetically modified dendritic cell vaccine is a much more potent activator of CD4 and CD8 T cells than peptide- or protein-loaded counterparts. Malowany JI; McCormick S; Santosuosso M; Zhang X; Aoki N; Ngai P; Wang J; Leitch J; Bramson J; Wan Y; Xing Z Mol Ther; 2006 Apr; 13(4):766-75. PubMed ID: 16343993 [TBL] [Abstract][Full Text] [Related]
9. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Kikuchi T; Miyazawa N; Moore MA; Crystal RG Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803 [TBL] [Abstract][Full Text] [Related]
10. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge. Krishnan L; Sad S; Patel GB; Sprott GD Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276 [TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
12. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635 [TBL] [Abstract][Full Text] [Related]
13. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro. Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500 [TBL] [Abstract][Full Text] [Related]
14. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells. Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701 [TBL] [Abstract][Full Text] [Related]
15. [Ad hTRP2 - mediated immunity against melanoma is enhanced by dendritic cells pulsed with peptide]. Tan XH; Liu C; Wan YH Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):658-61. PubMed ID: 17274369 [TBL] [Abstract][Full Text] [Related]
19. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells. Li T; Harada M; Tamada K; Abe K; Nomoto K Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518 [TBL] [Abstract][Full Text] [Related]
20. Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Chen Y; Emtage P; Zhu Q; Foley R; Muller W; Hitt M; Gauldie J; Wan Y Gene Ther; 2001 Feb; 8(4):316-23. PubMed ID: 11313806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]